Syndax Pharmaceuticals (Nasdaq: SNDX) and the World Orphan Drug Alliance (WODA) today announced a collaboration to expand access to the Company’s first-in-class menin inhibitor, Revuforj ® (revumenib) ...
The "In Situ Hybridization Market Report by Product, Technique, Application, End User, Countries and Company Analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback